Allarity Therapeutics, INC. (ALLR) — 10-Q Filings

10-Q Filings (6)

• Allarity Narrows Losses, Boosts R&D Amid Cash Burn Concerns — Nov 14, 2025 Risk: high
  Allarity Therapeutics, Inc. reported a net loss of $2.8 million for the three months ended September 30, 2025, a significant improvement from the $11.59 million
• Allarity Therapeutics Q2 2025: Assets $17M, Net Loss $2.4M — Aug 15, 2025 Risk: medium
  Allarity Therapeutics, Inc. reported its Q2 2025 financial results for the period ending June 30, 2025. The company had total assets of $17,075,338 and total li
• Allarity Therapeutics Q1 2025: Minimal Revenue, Assets $17M — May 9, 2025 Risk: medium
  Allarity Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported minimal revenue for the first quarter of 2025, with $0.000
• Allarity Therapeutics Q3 2024: Minimal Revenue, High Expenses — Nov 14, 2024 Risk: high
  Allarity Therapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported minimal revenue, with $0.0001 for the three months end
• Allarity Therapeutics Files Q2 2024 10-Q — Aug 5, 2024 Risk: medium
  Allarity Therapeutics, Inc. filed its 10-Q for the quarterly period ended June 30, 2024. The company, incorporated in Delaware, is based in Boston, MA, and oper
• Allarity Therapeutics, Inc. Files 10-Q for Period Ending March 31, 2024 — May 14, 2024 Risk: low
  Allarity Therapeutics, Inc. (ALLR) filed a Quarterly Report (10-Q) with the SEC on May 14, 2024. Allarity Therapeutics, Inc. filed a 10-Q report for the quarter

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX